Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial

Alberto Forteza, Arturo Evangelista, Violeta Sánchez, Gisela Teixidó-Turà, Paz Sanz, Laura Gutiérrez, Teresa Gracia, Jorge Centeno, José Rodríguez-Palomares, Juan Jose Rufilanchas, José Cortina, Ignacio Ferreira-González, David García-Dorado

Research output: Contribution to journalArticleResearchpeer-review

67 Citations (Scopus)

Abstract

© 2015 Published on behalf of the European Society of Cardiology. Aims To determine the efficacy of losartan vs. atenolol in aortic dilation progression in Marfan syndrome (MFS) patients. Methods and results A phase IIIb, randomized, parallel, double-blind study was conducted in 140 MFS patients, age range: 5-60 years, with maximum aortic diameter <45 mm who received losartan (n = 70) or atenolol (n = 70). Doses were raised to a maximum of 1.4 mg/kg/day or 100 mg/day. The primary end-point was the change in aortic root and ascending aorta maximum diameter indexed by body surface area on magnetic resonance imaging after 36 months of treatment. No serious drug-related adverse effects were observed. Five patients presented aortic events during a follow-up (one in the losartan and four in the atenolol groups, P = 0.366). After 3 years of follow-up, aortic root diameter increased significantly in both groups: 1.1 mm (95% CI 0.6-1.6) in the losartan and 1.4 mm (95% CI 0.9-1.9) in the atenolol group, with aortic dilatation progression being similar in both groups: absolute difference between losartan and atenolol -0.3 mm (95% CI -1.1 to 0.4, P = 0.382) and indexed by BSA -0.5 mm/m 2 (95% CI -1.2 to 0.1, P = 0.092). Similarly, no significant differences were found in indexed ascending aorta diameter changes between the losartan and atenolol groups: -0.3 mm/m 2 (95% CI -0.8 to 0.3, P = 0.326). Conclusion Among patients with MFS, the use of losartan compared with atenolol did not result in significant differences in the progression of aortic root and ascending aorta diameters over 3 years of follow-up.
Original languageEnglish
Pages (from-to)978-985
JournalEuropean Heart Journal
Volume37
Issue number12
DOIs
Publication statusPublished - 21 Mar 2016

Keywords

  • Aorta
  • Losartan
  • Magnetic resonance imaging
  • Marfan

Fingerprint Dive into the research topics of 'Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: A randomized clinical trial'. Together they form a unique fingerprint.

Cite this